Topical Glucocorticoid Use and the Risk of Posttransplant Diabetes
Systemically administered glucocorticoids constitute an essential part of the immunosuppressive regimen for transplant recipients, yet their known risks of causing hyperglycemia or posttransplant diabetes require close monitoring and minimisation of use, when possible, to prevent detrimental effects...
Saved in:
Main Authors: | Simon Bøtker, Henrik Birn, Lara Aygen Øzbay |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-01-01
|
Series: | Case Reports in Endocrinology |
Online Access: | http://dx.doi.org/10.1155/2023/3648178 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Posttransplant Metabolic Syndrome
by: M. Shadab Siddiqui, et al.
Published: (2012-01-01) -
An Unusual Immediate Posttransplant Eruption
by: Ravi K. Mallavarapu, et al.
Published: (2025-02-01) -
Preconditioning Serum Levels of Endothelial Cell-Derived Molecules and the Risk of Posttransplant Complications in Patients Treated with Allogeneic Stem Cell Transplantation
by: Roald Lindås, et al.
Published: (2014-01-01) -
HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide
by: Andrea Bacigalupo, et al.
Published: (2016-01-01) -
Posttransplant Lymphoproliferative Disease Presenting as an Extracranial Mass
by: Reuben J. Arasaratnam, et al.
Published: (2017-01-01)